Market Introduction
Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.
Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the Middle East & Africa hematuria treatment market.
In the MEA region, the number of patients hospitalized in intensive care units (ICU) is rising, as is the number of pharmaceuticals prescribed, creating many diagnostic and therapeutic problems for already overburdened healthcare systems. COVID-19 symptoms are mostly seen in the pulmonary system, but urogenital manifestations and/or consequences are given special attention. The risk of serious infection is higher in older patients with CKD, and AKI is linked to a high fatality rate. Thus, it was necessary to monitor the kidney function of patients with severe COVID-19, and CRRT for protecting kidney function and cytokine elimination for critically ill patients was critical to improving recovery. COVID-19 infection, on the other hand, appears to have ramifications for the urogenital tract. When treating COVID-19, urogenital organs should be considered.
Market Overview and Dynamics
The Middle East & Africa hematuria treatment market is projected to reach US$ 46.8 million by 2028 from US$ 42.0 million in 2021; it is anticipated to grow at a CAGR of 1.5% from 2021 to 2028. Chronic kidney disease (CKD) is a common and life-threatening condition that affects a larger population. There are various types of CKDs, such as kidney stones, glomerulonephritis, polycystic kidney disease, and urinary tract infections. CKD is one of the key causes behind the prevalence of hematuria. In addition, the prevalence of UTI among women over 65 years of age is about 20% compared to the overall population, which is about 11%. Currently, the Middle East & Africa hematuria treatment market is gaining significantly from the increasing prevalence of associated indications.
Key Market Segments
In terms of type, the macroscopic hematuria segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the Middle East & Africa hematuria treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in Middle East & Africa are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.
Reasons to Buy Report
- To understand the Middle East & Africa hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the Middle East & Africa hematuria treatment market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the Middle East & Africa hematuria treatment market based on various segments for the period 2021–2028
MIDDLE EAST & AFRICA HEMATURIA TREATMENT MARKET SEGMENTATION
- Drugs
- Therapies
- Others
By Indication
- Urinary Tract Infections
- Kidney Stones
- Urethritis
- Blood Cancer
- Bladder Stones
- Prostate Cancer
- Cystitis
- Trauma
- Vigorous Exercise
- Polycystic Kidney Disease
- Endometriosis
- Menstruation
By Type
- Macroscopic Hematuria
- Microscopic Hematuria
- Idiopathic Hematuria
- Jogger’s Hematuria
By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASC's)
- Others
By Country
-
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Companies Mentioned
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
Middle East & Africa Hematuria Treatment Market Strategic Insights
Middle East & Africa Hematuria TreatmentMarket Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 42.0 Million |
| Market Size by 2028 | US$ 46.8 Million |
| CAGR (2021 - 2028) | 1.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| Middle East and Africa | South Africa, Saudi Arabia, UAE, Rest of Middle East and Africa |
| Market leaders and key company profiles |
|
Middle East & Africa Hematuria Treatment Market Country and Regional Insights
